Significant Shareholding Dealing

RNS Number : 9782S

Advanced Oncotherapy PLC

29 December 2016

 

ADVANCED ONCOTHERAPY PLC

("Advanced Oncotherapy" or the "Company")

Significant Shareholding Dealing

Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that AB Segulah, a significant shareholder of the Company, today purchased 150,000 ordinary shares of 25 pence each in the Company ("Ordinary Shares") at a price of 66 pence per Ordinary Share.

Following this transaction, AB Segulah now holds 3,219,451 Ordinary Shares representing 4.44% of the issued share capital of the Company.

Advanced Oncotherapy Plc	www.avoplc.com
Dr. Michael Sinclair, Executive Chairman	Tel: [phone]
Nicolas Serandour, CEO
Stockdale Securities (Nomad & Joint Broker)
Antonio Bossi / David Coaten	Tel: [phone]
Stifel Nicolaus Europe (Joint Broker)
Jonathan Senior / Ben Maddison	Tel: [phone]
Walbrook PR (Financial PR & IR)	Tel: [phone] or [e-mail]
Paul McManus / Anna Dunphy	Mob: [phone] / Mob: [phone]

About Advanced Oncotherapy Plc www.avoplc.com

Advanced Oncotherapy is a provider of particle therapy with protons that harnesses the best in modern technology. Advanced Oncotherapy's team "ADAM", based in Geneva, focuses on the development of a proprietary proton accelerator called Linac Image Guided Hadron Technology (LIGHT). LIGHT accelerates protons to the energy levels achieved in legacy machines but in a unit that is a quarter of the size and between a quarter and a fifth of the cost. This compact configuration delivers proton beams in a way that facilitates greater precision and electronic control which is not achievable with older technologies.

Advanced Oncotherapy will offer healthcare providers affordable systems that will enable them to treat cancer with an innovative technology as well as better health outcomes and lower treatment related side effects.

Advanced Oncotherapy continually monitors the market for any emerging improvements in delivering proton therapy and actively seeks working relationships with providers of these innovative technologies. Through these relationships, the Company will remain the prime provider of an innovative and cost-effective system for particle therapy with protons.

 

END

 

 

MSCAKCDQBBDDCBB